Treatment of Autoimmune Hemolytic Anemia
Start with prednisolone 1 mg/kg/day (rounded to nearest 20-25 mg) as first-line therapy, and add rituximab upfront if the patient is transfusion-dependent or shows minimal response after 2 weeks of corticosteroids. 1
First-Line Treatment Algorithm
Corticosteroids
- Prednisolone 1 mg/kg/day is standard first-line therapy for warm AIHA (wAIHA), rounded to the nearest 20-25 mg/day for practical dosing 1
- For unstable patients with severe hemolysis, use IV methylprednisolone 250 mg to 1 g daily for at least 3 days 1
- Response typically occurs within 2-3 weeks (defined as Hb improvement ≥20 g/L to at least 100 g/L, or normalization, without transfusion for ≥7 days) 1
When to Add Rituximab Upfront
Add rituximab immediately in combination with prednisolone if:
- Patient is transfusion-dependent, OR
- Minimal response after 2 weeks of high-dose prednisolone 1
This recommendation is based on two Phase 3 randomized trials showing that prednisolone plus rituximab achieved 75% complete response at 12 months versus only 30-40% with prednisolone alone, with sustained relapse-free survival of 60-70% at 2-3 years 1. This represents the highest quality evidence available and directly impacts mortality and quality of life by preventing relapses and minimizing prolonged steroid exposure.
Rituximab Dosing Options
- Standard dose: 375 mg/m² weekly for 4 weeks, OR 1000 mg separated by 2 weeks 1
- Low-dose alternative: 100 mg weekly for 4 weeks (for patients at increased infection risk) 1
Corticosteroid Tapering Strategy
Begin tapering once hemolysis has significantly reduced and Hb is stable, even before reticulocytosis and biochemical markers normalize 1:
- Reduce by 10-25 mg/week until reaching 20-25 mg/day
- Then reduce in smaller steps of 5-12.5 mg/week
- Limit total corticosteroid exposure to ≤3 months 1
Critical pitfall: If relapse occurs during tapering, do NOT increase prednisolone—instead, start second-line therapy immediately 1. This avoids the considerable toxicity of prolonged steroid exposure.
Second-Line Treatment (Persistent/Refractory Disease)
If Rituximab Not Used First-Line
- Rituximab is the preferred second-line option with 70-80% response rates when combined with corticosteroids 1
- Same dosing options as above (standard or low-dose)
Alternative Oral Immunosuppressants
If rituximab is contraindicated or already failed:
- Mycophenolate mofetil: 500 mg twice daily orally
- Azathioprine: 100 mg daily orally (check thiopurine methyltransferase levels first) 1
- Important caveat: Response may be delayed up to 3 months with these agents 1
Life-Threatening Refractory Disease
For severe, life-threatening wAIHA refractory to front-line therapies:
- Pulse IV cyclophosphamide: 500-1000 mg every 2-4 weeks for up to 4 doses 1
Third-Line Considerations
Splenectomy
Avoid splenectomy in patients who are:
- ≥65 years old
- At elevated thrombosis risk
- Have cardiopulmonary disease
- Have underlying immunodeficiency, lymphoproliferative disease, or other autoimmune conditions 1
Rationale: While splenectomy has 60-70% response rates, approximately one-third relapse, and it carries serious risks including:
- Overwhelming sepsis risk of 3-5% with up to 50% mortality
- Increased thrombosis risk (hazard ratio 5.2 for early VTE, 2.7 for late VTE) 1
- Much lower response in secondary AIHA (19% vs 82% complete responses) 1
If splenectomy is pursued, vaccinate against encapsulated organisms prior to procedure 1.
Special Situations
Mixed AIHA
- Prefer combination prednisolone and rituximab upfront with 375 mg/m² rituximab dosing 1
Secondary wAIHA
- Treat the underlying cause (e.g., chronic lymphocytic leukemia, solid organ malignancy, infection) in addition to AIHA-directed therapy 1
Supportive Care Essentials
Transfusions
- For end-organ ischemia (confusion, hypoxia, angina) or hemodynamic instability: transfuse Group O unmatched red cells immediately—the risk of morbidity/mortality far outweighs transfusion reaction risk 1
- For symptomatic or severe anemia (Hb <70 g/L), transfusion is indicated 1
Additional Measures
- Folic acid 5 mg daily to meet increased demands during compensatory erythropoiesis 1
- Prophylactic anticoagulation for severe hemolysis 2
- Recombinant erythropoietin when reticulocytopenia/inadequate bone marrow compensation is present 2
Evidence Quality Note
The 2026 Australian/New Zealand consensus guidelines 1 represent the most recent and comprehensive evidence, incorporating two Phase 3 randomized trials that fundamentally changed the treatment paradigm by demonstrating superior outcomes with upfront rituximab plus prednisolone. Recent real-world data from China 3 confirms these findings, showing 88% ORR and 60% sustained remission with combination therapy versus 61.3% ORR and only 10.7% sustained remission with glucocorticoid monotherapy.
The key paradigm shift: Minimize steroid exposure to ≤3 months and use rituximab early rather than prolonging steroids or rushing to splenectomy, as this approach optimizes both efficacy and quality of life while reducing treatment-related morbidity.